{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T09:31:28Z","timestamp":1782293488943,"version":"3.54.5"},"reference-count":38,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services","award":["HHSN272201700040I\/HHSN27200007"],"award-info":[{"award-number":["HHSN272201700040I\/HHSN27200007"]}]},{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services","award":["A07"],"award-info":[{"award-number":["A07"]}]},{"name":"Preclinical Models of Infectious Diseases Task Order","award":["HHSN272201700040I\/HHSN27200007"],"award-info":[{"award-number":["HHSN272201700040I\/HHSN27200007"]}]},{"name":"Preclinical Models of Infectious Diseases Task Order","award":["A07"],"award-info":[{"award-number":["A07"]}]},{"name":"UTMB internal funding","award":["HHSN272201700040I\/HHSN27200007"],"award-info":[{"award-number":["HHSN272201700040I\/HHSN27200007"]}]},{"name":"UTMB internal funding","award":["A07"],"award-info":[{"award-number":["A07"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Favipiravir is a ribonucleoside analogue that has been explored as a therapeutic for the treatment of Ebola Virus Disease (EVD). Promising data from rodent models has informed nonhuman primate trials, as well as evaluation in patients during the 2013\u20132016 West African EVD outbreak of favipiravir treatment. However, mixed results from these studies hindered regulatory approval of favipiravir for the indication of EVD. This study examined the influence of route of administration, duration of treatment, and treatment schedule of favipiravir in immune competent mouse and guinea pig models using rodent-adapted Zaire ebolavirus (EBOV). A dose of 300 mg\/kg\/day of favipiravir with an 8-day treatment was found to be fully effective at preventing lethal EVD-like disease in BALB\/c mice regardless of route of administration (oral, intraperitoneal, or subcutaneous) or whether it was provided as a once-daily dose or a twice-daily split dose. Preclinical data generated in guinea pigs demonstrates that an 8-day treatment of 300 mg\/kg\/day of favipiravir reduces mortality following EBOV challenge regardless of route of treatment or duration of treatments for 8, 11, or 15 days. This work supports the future translational development of favipiravir as an EVD therapeutic.<\/jats:p>","DOI":"10.3390\/v16071101","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T07:16:07Z","timestamp":1720509367000},"page":"1101","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3630-0588","authenticated-orcid":false,"given":"Dylan M.","family":"Johnson","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"},{"name":"Department of Biotechnology & Bioengineering, Sandia National Laboratories, Livermore, CA 945501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7034-2602","authenticated-orcid":false,"given":"Terry","family":"Juelich","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte K.","family":"Kalveram","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Perez","sequence":"additional","affiliation":[{"name":"Office of Biosafety, Texas A&M University, College Station, TX 77843, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1047-5153","authenticated-orcid":false,"given":"Jeanon","family":"Smith","sequence":"additional","affiliation":[{"name":"Office of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grimes","sequence":"additional","affiliation":[{"name":"Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Garron","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maricela","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Massey","sequence":"additional","affiliation":[{"name":"Office of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Brasel","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"},{"name":"Office of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W. C.","family":"Beasley","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"},{"name":"Office of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8413-8960","authenticated-orcid":false,"given":"Alex N.","family":"Freiberg","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Comer","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"},{"name":"Office of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Feldmann, H., Slenczka, W., and Klenk, H.-D. (1996). Emerging and Reemerging of Filoviruses, Springer.","DOI":"10.1007\/978-3-7091-7482-1_9"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/infdis\/jiw207","article-title":"Discovery and description of Ebola Zaire virus in 1976 and relevance to the West African epidemic during 2013\u20132016","volume":"214","author":"Breman","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.15585\/mmwr.su6503a2","article-title":"Overview, control strategies, and lessons learned in the CDC response to the 2014\u20132016 Ebola epidemic","volume":"65","author":"Bell","year":"2016","journal-title":"MMWR Suppl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1016\/S2666-5247(22)00264-6","article-title":"Ebola treatment: Progressing with pragmatism","volume":"3","author":"Microbe","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S1473-3099(22)00607-7","article-title":"New guidelines for treatment of Ebola virus disease","volume":"22","author":"Burki","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/8755122520950692","article-title":"Ervebo (Ebola Zaire vaccine, live\/rVSV\u0394G-ZEBOV-GP): The first licensed vaccine for the prevention of Ebola virus disease","volume":"36","author":"Piszczatoski","year":"2020","journal-title":"J. Pharm. Technol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40265-020-01452-3","article-title":"REGN-EB3: First approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40265-021-01483-4","article-title":"Ansuvimab: First approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41541-022-00564-z","article-title":"Non-human primate to human immunobridging demonstrates a protective effect of Ad26. ZEBOV, MVA-BN-Filo vaccine against Ebola","volume":"7","author":"Bockstal","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S2666-5247(22)00123-9","article-title":"Effects of therapies for Ebola virus disease: A systematic review and network meta-analysis","volume":"3","author":"Gao","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Yu, X., and Saphire, E.O. (2022). Development and Structural Analysis of Antibody Therapeutics for Filoviruses. Pathogens, 11.","DOI":"10.3390\/pathogens11030374"},{"key":"ref_13","first-page":"1","article-title":"A Review on Antiviral Activity of Favipiravir","volume":"34","author":"Marathakam","year":"2022","journal-title":"J. Pharm. Res. Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/infdis\/jiac135","article-title":"Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials","volume":"226","author":"Hayden","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14787210.2021.1866545","article-title":"A review on favipiravir: The properties, function, and usefulness to treat COVID-19","volume":"19","author":"Hashemian","year":"2021","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2018.01.011","article-title":"Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model","volume":"151","author":"Zhu","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Guedj, J., Piorkowski, G., Jacquot, F., Madelain, V., Nguyen, T.H.T., Rodallec, A., Gunther, S., Carbonnelle, C., Mentr\u00e9, F., and Raoul, H. (2018). Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Med., 15.","DOI":"10.1371\/journal.pmed.1002535"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e01412","DOI":"10.1016\/j.idcr.2022.e01412","article-title":"High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea","volume":"27","author":"Eloy","year":"2022","journal-title":"IDCases"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nguyen, T.H.T., Guedj, J., Anglaret, X., Laou\u00e9nan, C., Madelain, V., Taburet, A.-M., Baize, S., Sissoko, D., Pastorino, B., and Rodallec, A. (2017). Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Neglected Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005389"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sissoko, D., Laouenan, C., Folkesson, E., M\u2019lebing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., and Danel, C. (2016). Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): A historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002066"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/infdis\/jiz078","article-title":"Laboratory findings, compassionate use of Favipiravir, and outcome in patients with Ebola virus disease, guinea, 2015\u2014A retrospective observational study","volume":"220","author":"Kerber","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S649","DOI":"10.1093\/infdis\/jiy303","article-title":"Postexposure protective efficacy of T-705 (Favipiravir) against Sudan virus infection in Guinea pigs","volume":"218","author":"Rahim","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Reynard, S., Gloaguen, E., Baillet, N., Madelain, V., Guedj, J., Raoul, H., de Lamballerie, X., Mullaert, J., and Baize, S. (2021). Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates. PLoS Neglected Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009300"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Escaffre, O., Juelich, T.L., Neef, N., Massey, S., Smith, J., Brasel, T., Smith, J.K., Kalveram, B., Zhang, L., and Perez, D. (2021). STAT-1 Knockout Mice as a Model for Wild-Type Sudan Virus (SUDV). Viruses, 13.","DOI":"10.3390\/v13071388"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Comer, J.E., Escaffre, O., Neef, N., Brasel, T., Juelich, T.L., Smith, J.K., Smith, J., Kalveram, B., Perez, D.D., and Massey, S. (2019). Filovirus virulence in interferon \u03b1\/\u03b2 and \u03b3 double knockout mice, and treatment with favipiravir. Viruses, 11.","DOI":"10.3390\/v11020137"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2017.12.021","article-title":"Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus","volume":"151","author":"Bixler","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1038\/s41467-018-06215-z","article-title":"Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies","volume":"9","author":"Madelain","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1086\/514292","article-title":"A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever","volume":"179","author":"Bray","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1086\/514305","article-title":"Pathogenesis of experimental Ebola virus infection in guinea pigs","volume":"179","author":"Connolly","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Mendenhall, M., Russell, A., Smee, D.F., Hall, J.O., Skirpstunas, R., Furuta, Y., and Gowen, B.B. (2011). Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS Neglected Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0001342"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2015.08.015","article-title":"Ebola virus dynamics in mice treated with favipiravir","volume":"123","author":"Madelain","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"14775","DOI":"10.1038\/srep14775","article-title":"The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset","volume":"5","author":"Safronetz","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gowen, B.B., Juelich, T.L., Sefing, E.J., Brasel, T., Smith, J.K., Zhang, L., Tigabu, B., Hill, T.E., Yun, T., and Pietzsch, C. (2013). Favipiravir (T-705) inhibits Junin virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. PLoS Neglected Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002614"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e01305-16","DOI":"10.1128\/AAC.01305-16","article-title":"Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses","volume":"61","author":"Madelain","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/psp4.12510","article-title":"Modeling favipiravir antiviral efficacy against emerging viruses: From animal studies to clinical trials","volume":"9","author":"Madelain","year":"2020","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/bdd.2275","article-title":"Favipiravir biotransformation in liver cytosol: Species and sex differences in humans, monkeys, rats, and mice","volume":"42","author":"Hanioka","year":"2021","journal-title":"Biopharm. Drug Dispos."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/7\/1101\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:11:56Z","timestamp":1760109116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/7\/1101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["v16071101"],"URL":"https:\/\/doi.org\/10.3390\/v16071101","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]}}}